The US Environmental Protection Agency's (EPA) work plan for the use of New Approach Methods (NAMs) was developed in response to EPA Administrator Andrew Wheeler's Guideline 2019, which aims to reduce the use of animal testing while maintaining the protection of humans and the environment.

The online Summer School of the Center for Alternatives to Animal Testing (CAAT) at the Johns Hopkins Bloomberg School of Public Health in Baltimore is currently running.

Some of the events can be attended free of charge.

Scientists at Empa in St. Gallen, Switzerland, are using cell cultures as well as mathematical comparison models and algorithms to determine the risks of nanoparticles, especially of Graphene, on humans.

Coronavirus is able to infect brain cells

Thursday, 18 June 2020 13:32

Scientists at the Center for Alternatives to Animal Testing (CAAT) at the Johns Hopkins Bloomberg School of Public Health in Baltimore have used an in vitro model to find out that the coronavirus SARS-CoV-2 can infect the human brain and multiply in the brain's nerve cells.

The Fraunhofer Institutes IGB, IZI, and IME as wells as the company Dynamic42 combine their competences and develop an immunocompetent lung-on-a-chip with human lung cells. With the model, they want to investigate the efficacy against SARS-Cov-2 of up to 40 different drugs from Fraunhofer libraries.

A British-Dutch research team has developed a new model of human embryonic stem cells (gastroloid) to study an early stage of human development.

In its current report 2020, the European Chemicals Agency (ECHA) informs, that there have been some changes in the use of alternatives to animal testing compared to the last study in 2017.

A peer-reviewed study by Hesperos Inc. based in Florida reports on how the company's human-on-a-chip technology can be used to study immune responses to treatment with biological therapeutics in multi-organ systemic diseases.

Scientists from Hesperos Inc., the University of Central Florida as well as from Michigan State University have developed a new human-on-a-chip system with which they have successfully investigated physiological effects of certain molecular forms of β amyloid proteins.

Munich scientists of the Ludwig Maximilian University have proven with a simple method that not only desired gene effects are achieved with the CRISPR/Cas9 gene scissors, but also unwanted side effects can occur.